iBio Inc (AMEX:IBIO)
$ 1.92 -0.062 (-3.13%) Market Cap: 16.56 Mil Enterprise Value: 28.59 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 36/100

Ibio Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2022 / 06:40PM GMT
Release Date Price: $192.4 (+10.04%)
Daniel Thengone
Oppenheimer & Co. Inc. - Analyst

All right. Hello, everyone. Welcome to day three of our Oppenheimer Healthcare Conference and thanks for joining us today. My name is Daniel [Thengone], I am a biotech research associate here at Oppenheimer. And it's my pleasure to introduce iBio. iBio is a plant-based biopharmaceutical company that is leveraging its FastPharming technologies to develop novel biopharmaceuticals in oncology, fibrotic diseases and infectious diseases.

From the company, we have CEO and Chairman, Tom Isett, to present. In terms of the format here, we'll have the company present for about 20, 25 minutes, followed by some time for Q&A. Please feel free to send over questions using the Q&A chat at the bottom of your screen, and I'll do my best to get to all of them.

With that, thank you very much, Tom, for joining us today, and please take it away.

Tom Isett
iBio, Inc. - CEO & Chairman of the Board

Great. Thanks, Daniel, and happy Thursday to you and everybody. Thanks for joining. We're going to be,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot